<DOC>
	<DOC>NCT00154193</DOC>
	<brief_summary>The main purpose of this study is to identify cyclosporine C2 levels during 12 months treatment , while cyclosporine microemulsion dosages are adjusted based on C0 cyclosporine blood samples, and retrospectively correlate C2 levels to outcome (renal function and incidence of acute rejections)</brief_summary>
	<brief_title>Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients receiving a first heart or bilateral or single lung transplant Patients for whom a triple maintenance immunosuppressive therapy consisting of cyclosporine microemulsion, steroids and mycophenolate mofetil (MMF)/ entericcoated mycophenolate sodium (ECMPS ,(or azathioprine) is indicated. Multiorgan transplants or previously transplanted organs Patients with the need of more than two cyclosporine microemulsion dosages per day Other protocoldefined inclusion/exclusion criteria may applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Heart transplant, lung transplant, renal function, cyclosporine C2 Levels</keyword>
</DOC>